Af­ter all the love and mon­ey, an­a­lysts spec­u­late that J&J may swoop in with a buy­out of­fer for Gen­mab

Gen­mab Chief Ex­ec­u­tive Jan van de Winkel doesn’t un­der­state his af­fec­tion for J&J. When the two com­pa­nies tied the knot over Darza­lex, the CEO de­scribed the phar­ma gi­ant as “the per­fect part­ner.”

And the af­fec­tion has been rec­i­p­ro­cat­ed. J&J’s Paul Stof­fels told Reuters’ Ben Hir­sh­cler just now that “we love the part­ner­ship” with Gen­mab. Their deal in­clud­ed a $20 mil­lion check yes­ter­day for their suc­cess in de­vel­op­ing Darza­lex (dara­tu­mum­ab) for amy­loi­do­sis — their first Phase III out­side of mul­ti­ple myelo­ma. And they’ve been mak­ing ma­jor head­way in ex­pand­ing the fran­chise for mul­ti­ple myelo­ma, with block­buster plans to ex­pand their pipeline col­lab­o­ra­tion as J&J hands over roy­al­ties rang­ing up to 20%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.